Researchers obtained FDA studies under the Freedom of Information Act (including unpublished research) for four antidepressants: Effexor, Paxil, ...
It is a serious study and one which has looked at not only Prozac (fluoxetine), but also Effexor (venlafaxine), Serzone (nefazodone) and Deroxat ...
A bottle of antidepressant pills named Effexor is shown March 23, 2004 photographed in Miami, Florida. The Food and Drug Administration asked makers of ...
The new drug is slated to replace the company's top-selling Effexor drug when a cheaper generic version will become available as early as this summer. ...
Pristiq will be the successor to Wyeth's Effexor XR, whose patent expires in two years. Sales of Effexor last year were $3.8 billion. ...
... on antidepressants rumbles on, Wyeth has got the green light from US regulators for Pristiq, a derivative of the firm’s blockbuster Effexor. ...
The reports are based on a UK study that examined 47 clinical trials on the effectiveness of fluoxetine, paroxetine, venlafaxine (Effexor) and nefazodone ...
The new version of Effexor, named Pristiq, is Wyeth's attempt at extending the sales lifecycle of its Effexor franchise, which begins to face patent ...
Effexor XR, Wyeth's extended-release depression drug, last year posted $3.8 billion, 17 percent of its total revenue. Cheaper generic competition is ...
Pristiq will be the successor to Wyeth's Effexor XR, whose patent expires in two years. Sales of Effexor last year were $3.8 billion. ...